Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
CDNL Amends Payment Structure for $357.5 Million Acquisition of Hughes Brothers Construction

CDNL Amends Payment Structure for $357.5 Million Acquisition of Hughes Brothers Construction

MT newswireMT newswire2026/10/19 12:16
08:16 AM EDT, 10/19/2026 (MT Newswires) -- Cardinal Infrastructure (CDNL) has agreed to an amendment to change the balance between cash and stock in its previously announced acquisition of Hughes Brothers Construction, the company said. The updated deal maintains the $357.5 million purchase price but changes the consideration to 60% cash and 40% Cardinal shares, from 50% of each previously, the company said. Under the new deal, Hughes Brothers' owners will receive approximately $214.5 million in cash and 5.3 million shares based on an issue price of $27.21 per share, it said. The amendment also changes the earnout so that sellers will be eligible to receive up to $162.5 million, based on Hughes Brothers' adjusted EBITDA for the 12 months ending June 30, 2027, payable 60% in cash and 40% in shares, the company said. The deal is still expected to close in Q4.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12